Results 41 to 50 of about 21,604,258 (289)
The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.
Francesco Paolo Tambaro +8 more
doaj +1 more source
In-depth analysis of the safety of CAR-T cell therapy for solid tumors
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong +33 more
doaj +1 more source
Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity
T-cell therapies have made significant improvements in cancer treatment over the last decade. One cellular therapy utilizing T-cells involves the use of a chimeric MHC-independent antigen-recognition receptor, typically referred to as a chimeric antigen ...
John T. Keane, Avery D. Posey
doaj +1 more source
Chimeric antigen receptor T‐cell therapies: Optimising the dose [PDF]
Lymphocytes such as T‐cells can be genetically transduced to express a synthetic chimeric antigen receptor (CAR) that re‐directs their cytotoxic activity against a tumour‐expressed antigen of choice. Autologous (patient‐derived) CAR T‐cells have been licensed to treat certain relapsed and refractory B‐cell malignancies, and numerous CAR T‐cell products
Nathaniel Dasyam +2 more
openaire +2 more sources
Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years.
Xiaodi Zhang +7 more
doaj +1 more source
Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
Chimeric antigen receptor (CAR) T-cells targeting CD19 have drastically improved the outcomes of B-cell malignancies; however, the success has not yet extended to myeloid malignancies such as acute myeloid leukemia (AML).
Gergis, Usama, MD, MBA +5 more
core +3 more sources
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors [PDF]
The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors.
Daniel T, Harris, David M, Kranz
openaire +2 more sources
Cytomegalovirus (CMV) retinitis is a rare end-organ disease of CMV infection and is a marker of severe immunosuppression, especially in human immunodeficiency virus (HIV)-positive patients.
Mingming Zhang +7 more
core +1 more source
Chimeric antigen receptor T cell therapy represents a transformative advancement in immunotherapy, wherein engineered T cells target tumor antigens, achieving high response rates in hematological malignancies.
Zhitong Guo, Mengjie Zhang, Yuanyu Huang
doaj +1 more source
Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular Cloning
Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular ...
Anthony J Bais (13285305)
core +1 more source

